JP2005511038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511038A5 JP2005511038A5 JP2003548768A JP2003548768A JP2005511038A5 JP 2005511038 A5 JP2005511038 A5 JP 2005511038A5 JP 2003548768 A JP2003548768 A JP 2003548768A JP 2003548768 A JP2003548768 A JP 2003548768A JP 2005511038 A5 JP2005511038 A5 JP 2005511038A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- human factor
- modified human
- seq
- substitutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 47
- 102000057593 human F8 Human genes 0.000 claims 47
- 229960000900 human factor viii Drugs 0.000 claims 44
- 238000006467 substitution reaction Methods 0.000 claims 36
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 26
- 238000000034 method Methods 0.000 claims 26
- 150000001413 amino acids Chemical group 0.000 claims 7
- 235000004279 alanine Nutrition 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000001690 Factor VIII Human genes 0.000 claims 5
- 108010054218 Factor VIII Proteins 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 229960000301 factor viii Drugs 0.000 claims 5
- 230000002829 reductive effect Effects 0.000 claims 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- 102000002110 C2 domains Human genes 0.000 claims 3
- 108050009459 C2 domains Proteins 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Chemical group 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33456901P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/037884 WO2003047507A2 (en) | 2001-11-30 | 2002-11-27 | Factor viii c2 domain variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005511038A JP2005511038A (ja) | 2005-04-28 |
| JP2005511038A5 true JP2005511038A5 (enExample) | 2005-12-22 |
Family
ID=23307813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003548768A Pending JP2005511038A (ja) | 2001-11-30 | 2002-11-27 | 第ｖｉｉｉ因子ｃ２ドメインのバリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040249134A1 (enExample) |
| EP (1) | EP1456235A4 (enExample) |
| JP (1) | JP2005511038A (enExample) |
| CN (1) | CN1630666A (enExample) |
| AU (1) | AU2002364509A1 (enExample) |
| CA (1) | CA2462966A1 (enExample) |
| MX (1) | MXPA04005079A (enExample) |
| WO (1) | WO2003047507A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
| US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| JP4644663B2 (ja) | 2003-06-03 | 2011-03-02 | セル ジェネシス インコーポレイテッド | ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法 |
| EP1682106A4 (en) * | 2003-10-30 | 2008-06-11 | Univ Emory | MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES |
| JP2007536230A (ja) * | 2004-05-03 | 2007-12-13 | エモリー ユニバーシティ | ブタＢドメイン欠損ｆＶＩＩＩの投与方法 |
| MY185597A (en) * | 2005-09-20 | 2021-05-24 | Avantor Performance Mat Inc | Vegetarian protein a preparation and methods thereof |
| FR2913020B1 (fr) | 2007-02-23 | 2012-11-23 | Biomethodes | Nouveaux facteurs viii pour le traitement des hemophiles de type a |
| IT1394522B1 (it) | 2009-01-09 | 2012-07-05 | Invatec Technology Ct Gmbh | Dispositivo medicale con rilascio di farmaco |
| HUE029454T2 (en) | 2009-11-13 | 2017-03-28 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| CA2780763A1 (en) * | 2009-11-13 | 2011-05-19 | Puget Sound Blood Center | Factor viii b cell epitope variants having reduced immunogenicity |
| AU2011303916A1 (en) * | 2010-09-15 | 2013-03-21 | Novo Nordisk A/S | Factor VIII variants having a decreased cellular uptake |
| CA2816575C (en) | 2010-11-05 | 2019-06-11 | Baxter Healthcare S.A. | A new variant of antihemophilic factor viii having increased specific activity |
| EP3107561A4 (en) * | 2014-02-19 | 2017-12-20 | Bloodworks | Factor viii b cell epitope variants having reduced immunogenicity |
| EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| WO2025164792A1 (ja) * | 2024-02-02 | 2025-08-07 | 学校法人自治医科大学 | 高比活性／高分泌発現型の第ｖｉｉｉ因子改変体、高発現型の第ｖｉｉｉ因子コード核酸及びそれらの用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) * | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| JPH0788399B2 (ja) * | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
| US5004803A (en) * | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| US6180371B1 (en) * | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
| US5364771A (en) * | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5888974A (en) * | 1992-04-07 | 1999-03-30 | Emory University | Hybrid human/animal factor VIII |
| US5744446A (en) * | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| US6376463B1 (en) * | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5663060A (en) * | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
| US5859204A (en) * | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| MXPA03002256A (es) * | 2000-09-19 | 2003-09-10 | Univ Emory | Factor viii modificado. |
-
2002
- 2002-11-27 MX MXPA04005079A patent/MXPA04005079A/es not_active Application Discontinuation
- 2002-11-27 US US10/491,464 patent/US20040249134A1/en not_active Abandoned
- 2002-11-27 CN CNA028238451A patent/CN1630666A/zh active Pending
- 2002-11-27 WO PCT/US2002/037884 patent/WO2003047507A2/en not_active Ceased
- 2002-11-27 EP EP02799885A patent/EP1456235A4/en not_active Withdrawn
- 2002-11-27 JP JP2003548768A patent/JP2005511038A/ja active Pending
- 2002-11-27 CA CA002462966A patent/CA2462966A1/en not_active Abandoned
- 2002-11-27 AU AU2002364509A patent/AU2002364509A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511038A5 (enExample) | ||
| JP2004525608A5 (enExample) | ||
| Arai et al. | Amino‐acid sequence of feather keratin from fowl | |
| Benedetti | X‐ray crystallography of peptides: The contributions of the Italian laboratories | |
| RU2003107100A (ru) | Модифицированный фактор viii | |
| CZ286889B6 (en) | Parathormone derivatives and pharmaceutical preparations in which they are comprised | |
| Mtwisha et al. | HSP 12 is a LEA-like protein in Saccharomyces cerevisiae | |
| KR950704486A (ko) | 성분b로 명명된 신규 단백질(new protein from urine named component b) | |
| ATE509943T1 (de) | Peptidreinigung mittels metallionenaffinitätschromatographie | |
| CN115443288A (zh) | 一种免疫球蛋白降解酶IdeE的突变体 | |
| HU205368B (en) | Process for producing peptides with antiaggregational effect and pharmaceutical compositions comprising same as active ingredient | |
| US4659694A (en) | Prothymosin alpha | |
| JP2020517260A5 (enExample) | ||
| WO2002008426A3 (en) | Fh-binding protein of streptococcus pneumoniae | |
| JP2008521795A5 (enExample) | ||
| Vuilleumier et al. | Synthetic peptide and template‐assembled synthetic protein models of the hen egg white lysozyme 87–97 helix: Importance of a protein‐like framework for conformational stability in a short peptide sequence | |
| Browning et al. | Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers | |
| WO2004014937A3 (en) | Thrombin peptide derivatives | |
| WO2008003707A2 (en) | Minimized small peptides with high affinity for factor viii and factor viii-like proteins | |
| JP2004505640A5 (enExample) | ||
| WO2001027136A3 (fr) | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire | |
| WO2003090667A3 (fr) | Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16 | |
| CA2522329A1 (en) | Inhibitors of coronavirus | |
| RU2010120571A (ru) | Тимус-специфический белок | |
| WO1995000546A1 (en) | Endothelin-antagonizing peptide |